Table 2

Summary of clinical features in Reactome pathway clusters

Clusters by LLDAS (n=310)Clusters by DORIS remission (n=321)
Feature, n (%) Cluster 1
(n=91)
Cluster 2
(n=148)
Cluster 3
(n=71)
P value Cluster 1
(n=93)
Cluster 2
(n=142)
Cluster 3
(n=86)
P value
DORIS remission21 (23.1%)31 (20.9%)4 (5.6%) <0.010 25 (29.9%)25 (17.6%)6 (7.0%) 0.001
LLDAS49 (53.8%)70 (47.3%)12 (16.9%) <0.001 52 (55.9%)63 (44.4%)16 (18.6%) <0.001
CNS8 (8.8%)13 (8.8%)5 (7.0%)NS8 (8.6%)11 (7.7%)7 (8.1%)NS
Musculoskeletal8 (8.8%)21 (14.2%)19 (26.8%) <0.010 9 (8.6%)20 (14.1%)20 (23.3%) <0.050
Renal11 (12.1%)30 (20.3%)24 (33.8%) <0.005 11 (11.8%)29 (20.4%)26 (30.2%) 0.010
Mucocutaneous38 (41.8%)73 (49.3%)44 (62%) <0.050 39 (41.9%)71 (50.0%)51 (59.3%)NS
Serositis1 (1.1%)3 (2.0%)3 (4.2%)NS1 (1.1%)3 (2.1%)3 (3.5%)NS
Positive serology59 (64.8%)86 (58.1%)52 (73.2%)NS62 (66.7%)78 (54.9%)62 (72.1%) <0.050
Low C3/C4 levels42 (46.1%)70 (47.3%)45 (63.4%)0.05046 (49.5%)59 (41.5%)52 (60.5%) <0.050
Anti-dsDNA (+)33 (36.3%)51 (34.5%)37 (52.1%) <0.050 36 (38.7%)47 (33.1%)43 (50%) <0.050
Altered CBC18 (19.8%)28 (18.9%)17 (23.9%)NS17 (18.3%)29 (20.4%)21 (24.4%)NS
Leucopenia16 (17.6%)21 (14.2%)14 (19.7%)NS15 (16.1%)22 (15.5%)17 (19.8%)NS
Thrombocytopenia3 (3.3%)11 (7.4%)6 (8.4%)NS4 (4.3%)9 (6.3%)8 (9.3%)NS
Hydroxychloroquine68 (74.7%)102 (69.0%)53 (74.6%)NS70 (75.3%)95 (66.9%)66 (76.7%)NS
Immunosuppressants18 (19.8%)44 (29.7%)40 (56.3%) <0.001 18 (19.4%)42 (29.6%)46 (53.5%) <0.001
  • Prevalence of clinical and laboratory features in clusters from significantly differential Reactome pathways.

  • P values are derived from Pearson’s χ squared (χ2) or Fisher’s exact tests.

  • Significant results are in bold.

  • (+),increased binding.

  • C3, complement protein 3; C4, complement protein 4; CBC, complete blood count; CNS, central nervous system involvement; DORIS, definitions of remission in systemic lupus erythematosus; LLDAS, lupus low disease activity state; NS, non-significant p-value.